Apyx medical corporation announces peer-reviewed clinical publication evaluating the safety of renuvion® following liposuction in multiple areas of the body

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq: apyx) (“apyx medical;” the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today announced the publication of a peer-reviewed article in the aesthetic surgery journal open forum, which evaluated the use of renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. “we are excited to see the publication of this.
APYX Ratings Summary
APYX Quant Ranking